Top

Journal of Neurology

Published in:

01-10-2014 | Letter to the Editors

First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS

Authors: Clas Malmeström, Bengt A. Andersson, Jan Lycke

Published in: Journal of Neurology | Issue 10/2014

Excerpt

Dear Sirs, …

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, Investigators C-MI (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828CrossRefPubMed

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, Investigators C-MI (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839CrossRefPubMed

Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77:573–579CrossRefPubMed

Knip M, Korhonen S, Kulmala P, Veijola R, Reunanen A, Raitakari OT, Viikari J, Akerblom HK (2010) Prediction of type 1 diabetes in the general population. Diabetes Care 33:1206–1212PubMedCentralCrossRefPubMed

Nokoff N, Rewers M (2013) Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann NY Acad Sci 1281:1–15PubMedCentralCrossRefPubMed

Todd JA (2010) Etiology of type 1 diabetes. Immunity 32:457–467CrossRefPubMed

Watkins RA, Evans-Molina C, Blum JS, Dimeglio LA (2014) Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. Transl Res. doi:10.1016/j.trsl.2014.02.004 PubMedCentralPubMed

Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104:17040–17045PubMedCentralCrossRefPubMed

Ziegler AG, Nepom GT (2010) Prediction and pathogenesis in type 1 diabetes. Immunity 32:468–478PubMedCentralCrossRefPubMed

Title: First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS
Authors: Clas Malmeström
Bengt A. Andersson
Jan Lycke
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 10/2014
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-014-7448-y

At a glance: The STEP trials

Springer Medicine

First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2014

The evolution of mild parkinsonian signs in aging

Nikolaus Friedreich (1825–1882)

Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia

Detailing intra-lesional venous lumen shrinking in multiple sclerosis investigated by sFLAIR MRI at 7-T

Successful treatment of refractory absence status epilepticus with lacosamide

Teleneurology in stroke management: costs of service in different organizational models